DOCSLIB.ORG

A Guide to Vaccinology: from Basic Principles to New Developments

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
A Guide to Vaccinology: from Basic Principles to New Developments REVIEWS A guide to vaccinology: from basic principles to new developments Andrew J. Pollard 1,2 ✉ and Else M. Bijker1,2 Abstract | Immunization is a cornerstone of public health policy and is demonstrably highly cost-effective when used to protect child health. Although it could be argued that immunology has not thus far contributed much to vaccine development, in that most of the vaccines we use today were developed and tested empirically, it is clear that there are major challenges ahead to develop new vaccines for difficult-to-target pathogens, for which we urgently need a better understanding of protective immunity. Moreover, recognition of the huge potential and challenges for vaccines to control disease outbreaks and protect the older population, together with the availability of an array of new technologies, make it the perfect time for immunologists to be involved in designing the next generation of powerful immunogens. This Review provides an introductory overview of vaccines, immunization and related issues and thereby aims to inform a broad scientific audience about the underlying immunological concepts. Antigens Vaccines have transformed public health, particularly on infectious diseases to provide insight into the key Parts of the pathogen (such as since national programmes for immunization first issues facing immunologists today. We also provide proteins or polysaccharides) became properly established and coordinated in the some perspectives on current and future challenges that are recognized by the 1960s. In countries with high vaccine programme cov- in continuing to protect the world’s population from immune system and can be used to induce an immune erage, many of the diseases that were previously respon- common pathogens and emerging infectious threats. response by vaccination. sible for the majority of childhood deaths have essentially Communicating effectively about the science of vacci- disappeared1 (FIg. 1). The World Health Organization nation to a sceptical public is a challenge for all those Protection (WHO) estimates that 2–3 million lives are saved each engaged in vaccine immunobiology but is urgently The state in which an individual year by current immunization programmes, contributing needed to realign the dialogue and ensure public health8. does not develop disease after being exposed to a pathogen. to the marked reduction in mortality of children less than This can only be achieved by being transparent about 5 years of age globally from 93 deaths per 1,000 live births what we know and do not know, and by considering the in 1990 to 39 deaths per 1,000 live births in 2018 (REF.2). strategies to overcome our existing knowledge gaps. Vaccines exploit the extraordinary ability of the highly evolved human immune system to respond to, What is in a vaccine? and remember, encounters with pathogen antigens. A vaccine is a biological product that can be used to However, for much of history, vaccines have been devel- safely induce an immune response that confers protection oped through empirical research without the involve- against infection and/or disease on subsequent exposure ment of immunologists. There is a great need today for to a pathogen. To achieve this, the vaccine must contain improved understanding of the immunological basis antigens that are either derived from the pathogen or for vaccination to develop vaccines for hard-to-target produced synthetically to represent components of the pathogens (such as Mycobacterium tuberculosis, the bac- pathogen. The essential component of most vaccines 3 1Oxford Vaccine Group, terium that causes tuberculosis (TB)) and antigenically is one or more protein antigens that induce immune 4 Department of Paediatrics, variable pathogens (such as HIV) , to control outbreaks responses that provide protection. However, polysac- University of Oxford, that threaten global health security (such as COVID-19 charide antigens can also induce protective immune Oxford, UK. or Ebola)5,6 and to work out how to revive immune responses and are the basis of vaccines that have been 2NIHR Oxford Biomedical responses in the ageing immune system7 to protect developed to prevent several bacterial infections, such Research Centre, Oxford the growing population of older adults from infectious as pneumonia and meningitis caused by Streptococcus University Hospitals Trust, 9 Oxford, UK. diseases. pneumoniae, since the late 1980s . Protection conferred ✉e-mail: andrew.pollard@ In this Review, which is primarily aimed at a broad by a vaccine is measured in clinical trials that relate paediatrics.ox.ac.uk scientific audience, we provide a guide to the history immune responses to the vaccine antigen to clinical end https://doi.org/10.1038/ (BOx 1), development, immunological basis and remark- points (such as prevention of infection, a reduction in s41577-020-00479-7 able impact of vaccines and immunization programmes disease severity or a decreased rate of hospitalization). NATURE REVIEWS | IMMUNOLOGY VOLUME 21 | FEBRUARY 2021 | 83 REVIEWS a Diphtheria b Capsular group C meningococcus Introduction of 1,800 1,600 80,000 vaccination (1940) Introduction of 70,000 1,400 vaccination (1999) 60,000 1,200 50,000 1,000 40,000 800 30,000 600 Notifications 20,000 Number of cases 400 10,000 200 0 0 1914 1924 1934 1944 1954 1964 1974 1984 1994 2003 Year 1998/19991999/20002000/20012001/20022002/20032003/20042004/20052005/20062006/20072007/20082008/20092009/20102010/20112011/20122012/2013 Year c Polio d Haemophilus influenzae type B 1,000 Introduction of 900 vaccination (1992) 800 7,000 700 Introduction of 600 6,000 vaccination (1956) 5,000 500 4,000 400 3,000 300 Laboratory reports Laboratory 2,000 200 Notifications 1,000 100 0 0 1912 1922 1932 1942 1952 1962 1972 1982 1992 2006 1990199119921993199419951996199719981999200020012002200320042005 Year Year e Measles f Pertussis 900,000 800,000 Introduction of 200,000 700,000 vaccination (1968) 180,000 600,000 160,000 140,000 Introduction of vaccination (1950s) 500,000 120,000 Notifications 400,000 100,000 300,000 Notifications 80,000 60,000 200,000 40,000 100,000 20,000 0 0 1940 1944 1948 1952 1956 1960 1964 1968 1972 1976 1980 1984 1988 1992 1996 2000 2004 2008 2012 1950 1953 1956 1959 1962 1965 1968 1971 1974 1977 1980 1983 1986 1989 1992 1995 1998 2001 2004 2007 2010 2013 2016 Year Year Fig. 1 | The impact of vaccination on selected diseases in the UK. The introduction of vaccination against infectious diseases such as diphtheria (part a), capsular group C meningococcus (part b), polio (part c), Haemophilus influenzae type B (part d), measles (part e) and pertussis (part f) led to a marked decrease in their incidence. Of note, the increase in reports of H. influenzae type B in 2001 led to a catch-up vaccination campaign, after which the incidence reduced. For pertussis, a decline in vaccine coverage led to an increase in cases in the late 1970s and 1980s, but disease incidence reduced again after vaccine coverage increased. Adapted with permission from the Green Book, information for public health professionals on immunisation, Public Health England, contains public sector information licensed under the Open Government Licence v3.0. Finding an immune response that correlates with pro- The distinction between live and non-live vaccines tection can accelerate the development of and access to is important. The former may have the potential to repli- new vaccines10 (BOx 2). cate in an uncontrolled manner in immuno compromised Vaccines are generally classified as live or non-live individuals (for example, children with some pri- Attenuated (sometimes loosely referred to as ‘inactivated’) to distin- mary immunodeficiencies, or individuals with HIV A reduction in the virulence attenuated of a pathogen (through either guish those vaccines that contain replicating infection or those receiving immunosuppressive drugs), 11 deliberate or natural changes strains of the relevant pathogenic organism from those leading to some restrictions to their use . By contrast, in virulence genes). that contain only components of a pathogen or killed non-live vaccines pose no risk to immunocompromised whole organisms (Fig. 2). In addition to the ‘traditional’ individuals (although they may not confer protection in Virus-like particles live and non-live vaccines, several other platforms have those with B cell or combined immunodeficiency, as Particles constructed of viral proteins that structurally mimic been developed over the past few decades, including viral explained in more detail later). the native virus but lack the vectors, nucleic acid-based RNA and DNA vaccines, and Live vaccines are developed so that, in an immuno- viral genome. virus-like particles (discussed in more detail later). competent host, they replicate sufficiently to produce a 84 | FEBRUARY 2021 | VOLUME 21 www.nature.com/nri REVIEWS Adjuvant strong immune response, but not so much as to cause the portfolio of adjuvants is steadily expanding, with An agent used in a vaccine to significant disease manifestations (for example, the liposome-based adjuvants and oil-in-water emulsions enhance the immune response vaccines for measles, mumps, rubella and rotavirus, being licensed in the past few decades14. The mech- against the antigen. oral polio vaccine, the Mycobacterium bovis bacillus anism of action of aluminium salts (alum), although Danger signals Calmette–Guérin (BCG) vaccine for TB and live atten- extensively used as an adjuvant for more than 80 years, 15 Molecules that stimulate a uated influenza vaccine).
Load more

Recommended publications
  • Mercury and Vaccinations
    MERCURYMERCURY ANDAND VACCINESVACCINES FACT SHEET, OCTOBER 2006 What is the concern about mercury in vaccines? Thimerosal, also known as thiomersal, is a preservative used in a number of biological and pharmaceutical products, including some flu and many multi-dose vaccines used for child immunisation. Mercury makes up approximately 50% of the weight of thimerosal in the organic form of ethylmercury. Thimerosal has been added to products to help prevent the growth of microbes since the 1930s. As more has become known about the effects of mercury on human health, the use of thimerosal in vaccines became an issue of increasing concern. Over the years, with more and more childhood vaccinations recommended or required, the amount of mercury to which infants and young children are being exposed has signifi- cantly increased. While there were no toxic effects reported in the first study of thimerosal use in humans, published in 1931, the study was not specifically designed to examine toxicity and was flawed in a number of other ways.1 Studies of any potential effects of thimerosal exposure in humans are ongoing and no general scientific consensus currently exists. Questions have particularly arisen around a possible connection between thimerosal and autism. Additionally, research is being conducted into the relationship between mercury exposure and Alzheimer’s disease. In 2004, a statement from the European Agency for the Evaluation of Medicinal Products (EMEA) noted that new toxicity studies demonstrate that ethylmercury is less toxic than methylmercury, the form people ingest by eating some types of fish.2 The following year, the report of the Immunisation Safety Review Committee produced by the US Institute of Medicine found again that reviewed evidence “favours a rejection of a causal relationship between thimerosal-containing vaccines and autism.”3 Yet, others have suggested that new toxicological data shows that there could be a plausible connection between thi- merosal and neurological effects in animals and humans.
    [Show full text]
  • (ACIP) General Best Guidance for Immunization
    9. Special Situations Updates Major revisions to this section of the best practices guidance include the timing of intramuscular administration and the timing of clotting factor deficiency replacement. Concurrent Administration of Antimicrobial Agents and Vaccines With a few exceptions, use of an antimicrobial agent does not interfere with the effectiveness of vaccination. Antibacterial agents have no effect on inactivated, recombinant subunit, or polysaccharide vaccines or toxoids. They also have no effect on response to live, attenuated vaccines, except BCG vaccines. Antimicrobial or immunosuppressive agents may interfere with the immune response to BCG and should only be used under medical supervision (for additional information, see www.merck.com/product/usa/pi_circulars/b/bcg/bcg_pi.pdf). Antiviral drugs used for treatment or prophylaxis of influenza virus infections have no effect on the response to inactivated influenza vaccine (2). However, live, attenuated influenza vaccine should not be administered until 48 hours after cessation of therapy with antiviral influenza drugs. If feasible, to avoid possible reduction in vaccine effectiveness, antiviral medication should not be administered for 14 days after LAIV administration (2). If influenza antiviral medications are administered within 2 weeks after receipt of LAIV, the LAIV dose should be repeated 48 or more hours after the last dose of zanamavir or oseltamivir. The LAIV dose should be repeated 5 days after peramivir and 17 days after baloxavir. Alternatively, persons receiving antiviral drugs within the period 2 days before to 14 days after vaccination with LAIV may be revaccinated with another approved vaccine formulation (e.g., IIV or recombinant influenza vaccine). Antiviral drugs active against herpesviruses (e.g., acyclovir or valacyclovir) might reduce the efficacy of vaccines containing live, attenuated varicella zoster virus (i.e., Varivax and ProQuad) (3,4).
    [Show full text]
  • 362.Full.Pdf
    AMERICAN ACADEMY OF PEDIATRICS Committee on Infectious Diseases Policy Statement: Recommendations for the Prevention of Pneumococcal Infections, Including the Use of Pneumococcal Conjugate Vaccine (Prevnar), Pneumococcal Polysaccharide Vaccine, and Antibiotic Prophylaxis ABSTRACT. Heptavalent pneumococcal conjugate vac- lular pertussis; HbOC, Haemophilus influenzae type b conjugate cine (PCV7) is recommended for universal use in chil- vaccine; HIV, human immunodeficiency virus; AOM, acute otitis dren 23 months and younger, to be given concurrently media. with other recommended childhood vaccines at 2, 4, 6, and 12 to 15 months of age. For children 7 to 23 months he purpose of this report is to provide recom- old who have not received previous doses of PCV7, ad- ministration of a reduced number of doses is recom- mendations for use of the heptavalent pneumo- mended. Two doses of PCV7 are recommended for chil- Tcoccal conjugate vaccine (PCV7), Prevnar (Led- dren 24 to 59 months old at high risk of invasive erle Laboratories, Pearl River, NY; Wyeth-Ayerst pneumococcal infection—including children with func- Pharmaceuticals, Marietta, PA), and 23-valent pneumo- tional, anatomic, or congenital asplenia; infection with coccal polysaccharide (23PS) vaccines. In addition, rec- human immunodeficiency virus; and other predisposing ommendations for the continuing use of antibiotic pro- conditions—who have not been immunized previously phylaxis in children with sickle cell disease (SCD) and with PCV7. Recommendations have been made for use of asplenia will be given, and the use of antibiotics and 23-valent pneumococcal polysaccharide (23PS) vaccine in vaccines in children who attend out-of-home care will high-risk children to expand serotype coverage.
    [Show full text]
  • Maternal Vaccines - Safety in Pregnancy
    Journal Pre-proof Maternal Vaccines - Safety in pregnancy Dr Mala Arora, FRCOG (UK), FICOG, DObst (Ire), Chairperson, Vice President, Director, Consultant, Dr Rama Lakshmi, MBBS, MD PII: S1521-6934(21)00017-1 DOI: https://doi.org/10.1016/j.bpobgyn.2021.02.002 Reference: YBEOG 2112 To appear in: Best Practice & Research Clinical Obstetrics & Gynaecology Received Date: 14 August 2020 Revised Date: 18 November 2020 Accepted Date: 6 February 2021 Please cite this article as: Arora M, Lakshmi R, Maternal Vaccines - Safety in pregnancy, Best Practice & Research Clinical Obstetrics & Gynaecology, https://doi.org/10.1016/j.bpobgyn.2021.02.002. This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. © 2021 Published by Elsevier Ltd. Maternal Vaccines - Safety in pregnancy Dr Mala Arora FRCOG (UK),FICOG, DObst (Ire) Chairperson ICOG 2017 Vice President FOGSI 2011 Director Noble IVF Centre, sector 14, Faridabad Consultant Fortis La Femme, GK2 New Delhi India Dr Rama Lakshmi MBBS,MD Fellowship (IVF &Reproductive Medicine) Milann Fertility Centre Bengaluru India Corresponding author: Dr Mala Arora E-mail: [email protected];Journal [email protected] Pre-proof Abstract Vaccination during pregnancy is important for active immunity of the mother against serious infectious diseases, and also for passive immunity of the neonate to infectious diseases with high morbidity and mortality.
    [Show full text]
  • Safety of Immunization During Pregnancy a Review of the Evidence
    Safety of Immunization during Pregnancy A review of the evidence Global Advisory Committee on Vaccine Safety © World Health Organization 2014 All rights reserved. Publications of the World Health Organization are available on the WHO website (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications –whether for sale or for non-commercial distribution– should be addressed to WHO Press through the WHO website (www.who.int/about/licensing/copyright_form/en/index.html). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied.
    [Show full text]
  • (ACIP) General Best Guidance for Immunization
    8. Altered Immunocompetence Updates This section incorporates general content from the Infectious Diseases Society of America policy statement, 2013 IDSA Clinical Practice Guideline for Vaccination of the Immunocompromised Host (1), to which CDC provided input in November 2011. The evidence supporting this guidance is based on expert opinion and arrived at by consensus. General Principles Altered immunocompetence, a term often used synonymously with immunosuppression, immunodeficiency, and immunocompromise, can be classified as primary or secondary. Primary immunodeficiencies generally are inherited and include conditions defined by an inherent absence or quantitative deficiency of cellular, humoral, or both components that provide immunity. Examples include congenital immunodeficiency diseases such as X- linked agammaglobulinemia, SCID, and chronic granulomatous disease. Secondary immunodeficiency is acquired and is defined by loss or qualitative deficiency in cellular or humoral immune components that occurs as a result of a disease process or its therapy. Examples of secondary immunodeficiency include HIV infection, hematopoietic malignancies, treatment with radiation, and treatment with immunosuppressive drugs. The degree to which immunosuppressive drugs cause clinically significant immunodeficiency generally is dose related and varies by drug. Primary and secondary immunodeficiencies might include a combination of deficits in both cellular and humoral immunity. Certain conditions like asplenia and chronic renal disease also can cause altered immunocompetence. Determination of altered immunocompetence is important to the vaccine provider because incidence or severity of some vaccine-preventable diseases is higher in persons with altered immunocompetence; therefore, certain vaccines (e.g., inactivated influenza vaccine, pneumococcal vaccines) are recommended specifically for persons with these diseases (2,3). Administration of live vaccines might need to be deferred until immune function has improved.
    [Show full text]
  • Adult Vaccines
    What do flu, whooping cough, measles, shingles and pneumonia have in common? 1 They’re viruses that can make you very sick. 2 Vaccines can help prevent them. Protect yourself and those you care about. Get vaccinated at a network pharmacy near you. • Ask your pharmacist which vaccines are right for you. • Find out if your pharmacist can administer the recommended vaccinations. • Many vaccinations are covered by your plan at participating retail pharmacies. • Don’t forget to present your member ID card to the pharmacist at the time of service! The following vaccines are available and can be administered by pharmacists at participating network pharmacies: • Flu (seasonal influenza) • Meningitis • Travel Vaccines (typhoid, yellow • Tetanus/Diphtheria/Pertussis • Pneumonia fever, etc.) • Hepatitis • Rabies • Childhood Vaccines (MMR, etc.) • Human Papillomavirus (HPV) • Shingles/Zoster See other side for recommended adult vaccinations. The vaccinations you need ALL adults should get vaccinated for1: • Flu, every year. It’s especially important for pregnant women, older adults and people with chronic health conditions. • Tetanus, diphtheria and pertussis (whooping cough). Adults should get a one-time dose of the Tdap vaccine. It’s different from the tetanus vaccine (Td), which is given every 10 years. You may need additional vaccinations depending on your age1: Young adults not yet vaccinated need: Human papillomavirus (HPV) vaccine series (3 doses) if you are: • Female age 26 or younger • Male age 21 or younger • Male age 26 or younger who has sex with men, who is immunocompromised or who has HIV Adults born in the U.S. in 1957 or after need: Measles, mumps, rubella (MMR) vaccine2 Adults should get at least one dose of MMR vaccine, unless they’ve already gotten this vaccine or have immunity to measles, mumps and rubella Adults born in the U.S.
    [Show full text]
  • NHSGGC COVID Vaccine Faqs for Health and Social Care Staff Version 06 12/01/21
    NHSGGC COVID Vaccine FAQs for Health and Social Care Staff Version 06 12/01/21 Link to Green Book Chapter on COVID Vaccine MHRA vaccine approval JCVI recommendations CMO Letter COVID Vaccination Programme These FAQs relate to the Pzifer/BioNTech and AstraZeneca vaccine COVID-19 vaccine The FAQs will be frequently updated as new information becomes available Any printed version will quickly be outdated, always check the NHSGGC webpage for the most up-to-date advice Sections in this document 1. Vaccine Details 2. Current illness and COVID vaccine 3. Flu Vaccine 4. I am immunosuppressed 5. I have previously had a positive COVID test result 6. I have taken part in a COVID vaccine trial 7. Infection Control 8. Nursing Homes 9. Pregnancy and Breastfeeding 10. Allergies and anaphylaxis and other medications 11. Staff Queries – General 12. COVID Vaccines and other vaccines 13. How to become a vaccinator 14. Appointments NHSGGC COVID Vaccine FAQs for Health and Social Care Staff Version 06 12/01/21 Section 1: Vaccine Details Are they live vaccines? No. Neither the Pfizer-BioNTech vaccine nor the AstraZeneca (AZ) vaccine are live vaccines. The AZ vaccine uses an adenovirus, but as it cannot replicate it is not a live vaccine. How is the COVID-19 vaccine given? You will be given an injection in your upper arm. You will need two doses, the second will be offered 12 weeks after the first dose. During your vaccination, strict infection prevention and control measures will be in place. Will a vaccine booster be required? The schedule requires two doses.
    [Show full text]
  • Vaccines for Preteens
    | DISEASES and the VACCINES THAT PREVENT THEM | INFORMATION FOR PARENTS Vaccines for Preteens: What Parents Should Know Last updated JANUARY 2017 Why does my child need vaccines now? to get vaccinated. The best time to get the flu vaccine is as soon as it’s available in your community, ideally by October. Vaccines aren’t just for babies. Some of the vaccines that While it’s best to be vaccinated before flu begins causing babies get can wear off as kids get older. And as kids grow up illness in your community, flu vaccination can be beneficial as they may come in contact with different diseases than when long as flu viruses are circulating, even in January or later. they were babies. There are vaccines that can help protect your preteen or teen from these other illnesses. When should my child be vaccinated? What vaccines does my child need? A good time to get these vaccines is during a yearly health Tdap Vaccine checkup. Your preteen or teen can also get these vaccines at This vaccine helps protect against three serious diseases: a physical exam required for sports, school, or camp. It’s a tetanus, diphtheria, and pertussis (whooping cough). good idea to ask the doctor or nurse every year if there are any Preteens should get Tdap at age 11 or 12. If your teen didn’t vaccines that your child may need. get a Tdap shot as a preteen, ask their doctor or nurse about getting the shot now. What else should I know about these vaccines? These vaccines have all been studied very carefully and are Meningococcal Vaccine safe.
    [Show full text]
  • Pneumococcal Vaccine Timing for Adults Make Sure Your Patients Are up to Date with Pneumococcal Vaccination
    Pneumococcal Vaccine Timing for Adults Make sure your patients are up to date with pneumococcal vaccination. When both are If either vaccine is PCV13 and PPSV23 Two pneumococcal vaccines are recommended for adults: indicated, PCV13 inadvertently given should not be 13-valent pneumococcal conjugate vaccine (PCV13, Prevnar13®) should be given earlier than the administered during the ® before PPSV23 recommended window, 23-valent pneumococcal polysaccharide vaccine (PPSV23, Pneumovax 23) same office visit. whenever possible. do not repeat the dose. One dose of PCV13 is recommended for adults: One dose of PPSV23 is recommended for adults: 19 years or older with certain medical conditions and who have not 65 years or older, regardless of previous history of vaccination with previously received PCV13. See Table 1 for specific guidance. pneumococcal vaccines. Adults 65 years or older can discuss and decide, with their clinician, – Once a dose of PPSV23 is given at age 65 years or older, no to receive PCV13 if they have not previously received a dose (shared additional doses of PPSV23 should be administered. clinical decision-making). 19 through 64 years with certain medical conditions. – A second dose may be indicated depending on the medical condition. See Table 1 for specific guidance. Adults 65 years or older without an immunocompromising condition, CSF* leak, or cochlear implant For those who have not received any pneumococcal For those who have previously received 1 dose of vaccines, or those with unknown vaccination history PPSV23 at ≥ 65 years and no doses of PCV13 If patient and provider decide PCV13 is not to be given: If patient and provider decide PCV13 is not to be given: Administer 1 dose of PPSV23.
    [Show full text]
  • Vaccine Information for PARENTS and CAREGIVERS
    NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES Division of the National Health Laboratory Service VACCINE INFOR MATION FOR PARENTS & CAREGIVERS First Edition November 2016 Editors-in-Chief Nkengafac Villyen Motaze (MD, MSc, PhD fellow), Melinda Suchard (MBBCh, FCPath (SA), MMed) Edited by: Cheryl Cohen, (MBBCh, FCPath (SA) Micro, DTM&H, MSc (Epi), Phd) Lee Baker, (Dip Pharm) Lucille Blumberg, (MBBCh, MMed (Micro) ID (SA) FFTM (RCPS, Glasgow) DTM&H DOH DCH) Published by: Ideas Wise and Wonderful (IWW) for National Institute for Communicable Diseases (NICD) First Edition: Copyright © 2016 Contributions by: Clement Adu-Gyamfi (BSc Hons, MSc), Jayendrie Thaver (BSc), Kerrigan McCarthy, (MBBCh, FCPath (SA), DTM&H, MPhil (Theol) Kirsten Redman (BSc Hons), Nishi Prabdial-Sing (PhD), Nonhlanhla Mbenenge (MBBCh, MMED) Philippa Hime (midwife), Vania Duxbury (BSc Hons), Wayne Howard (BSc Hons) Acknowledgments: Amayeza, Vaccine Information Centre (http://www.amayeza-info.co.za/) Centre for Communicable Diseases Fact Sheets (http://www.cdc.gov/vaccines/hcp/vis/) World Health Organization Fact Sheets (http://www.who.int/mediacentre/factsheets/en/) National Department of Health, South Africa (http://www.health.gov.za/) Disclaimer This book is intended as an educational tool only. Information may be subject to change as schedules or formulations are updated. Summarized and simplified information is presented in this booklet. For full prescribing information and contraindications for vaccinations, please consult individual package inserts. There has been
    [Show full text]
  • Meningococcal Vaccine Q & a for Healthcare Providers
    Meningococcal Vaccine Q & A for Healthcare Providers School meningococcal vaccine requirements Q1: When did the school meningococcal vaccine requirement take effect? A1: The meningococcal vaccine school requirement took effect on September 1, 2016. Q2: For what grades is meningococcal vaccine required? A2: Meningococcal vaccine is currently required for students entering or attending grades 7 through 12 in public, private and parochial New York State (NYS) schools. Q3: How many doses of meningococcal vaccine are required for grades 7 through 11? A3: One dose of meningococcal conjugate vaccine (MenACWY; sometimes abbreviated as MCV4; brand names Menactra or Menveo) is required for entry into grades 7 through 11. Q4: How many doses of meningococcal vaccine are required for grade 12? A4: A total of two doses of MenACWY vaccine, administered a minimum of 8 weeks apart, are required for entry into grade 12. The second dose must be administered no sooner than 16 years of age. However, if the first dose of MenACWY vaccine was received at 16 years of age or older, then a second dose will not be required. The NYS school immunization requirements allow for a grace period of up to 4 days before the 16th birthday for receipt of the dose. A dose of vaccine received 5 or more days before the 16th birthday will not meet the 12th grade meningococcal vaccine requirement. Q5: Is serogroup B meningococcal vaccine (MenB vaccine) required for grade 12? A5: No, MenB vaccine is not required for school attendance in NYS. In addition, doses of MenB vaccine will not meet the NYS MenACWY vaccine requirement.
    [Show full text]